What is ABVX stock price today?

ABVX (Abivax Sa) stock is trading at $118.84 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ABVX stock going up or down today?

ABVX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ABVX stock now?

The decision to buy ABVX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ABVX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ABVX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ABVX stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ABVX is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ABVX's P/E ratio?

P/E ratio data for ABVX will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ABVX's market cap?

ABVX (Abivax Sa) has a market capitalization of $8.19 billion, making it a small-cap stock.

What is ABVX's price to book ratio?

ABVX trades at a price-to-book (P/B) ratio of 15.48, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ABVX pay dividends?

ABVX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ABVX's dividend yield?

ABVX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ABVX stock a good long-term investment?

ABVX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ABVX's revenue growth rate?

ABVX has shown revenue growth of -0.8% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for ABVX are available on our dashboard with complete income statement analysis.

What are the risks of investing in ABVX?

Key risks for ABVX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ABVX compare to its competitors?

Compare ABVX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ABVX's performance and positioning.

What is ABVX's stock price target for 2026?

Our AI model provides price targets for ABVX based on fundamental analysis: Bull case $154.49 (+30%), Base case $136.67 (+15%), Bear case $106.96 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ABVX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ABVX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ABVX's next earnings report?

ABVX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ABVX - Abivax Sa

NYSE * Health Care * Biotechnology

$118.84

+$1.74 (+1.49%)

About Abivax Sa

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

ABVX Key Statistics

Market Cap

$8.19B

P/B Ratio

15.48

EPS

$-3.58

Revenue Growth

-0.8%

Employees

How ABVX Compares to Peers

ABVX is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ABVX(This stock)	$8.19B	N/A	-1%	0.0%	-
AMGNAmgen Inc	$177.92B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.99B	19.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.16B	31.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.69B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.26B	15.1	0%	0.2%	vs BIIB

Abivax Sa Company Information

Headquarters: France
Website: www.abivax.com
Sector: Health Care
Industry: Biotechnology

Data Updated: January 21, 2026 at 2:24 AM EST

Ready to invest in ABVX?

Commission-free trading available. Affiliate links.

Upcoming Events for ABVX

Dashboard

Enter a ticker to analyze